Today Roche announced positive results from our Phase I clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of #obesity and type 2 #diabetes. The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo. Learn more here: https://bit.ly/3wKVSgD
关于我们
Carmot has been acquired by Roche in early 2024, making the company a member of the Roche Group. Carmot Therapeutics is a clinical-stage biotechnology company that is focused on advancing life-changing therapeutics for people with obesity and diabetes. We are utilizing Chemotype Evolution, a pioneering drug discovery platform, to identify novel incretin receptor signaling targets to develop a broad pipeline of therapeutics that have the potential to produce significant weight loss and improved glycemic control. We have three clinical candidates: CT-388, CT-868 and CT-996.
- 网站
-
https://carmot-therapeutics.us/
Carmot Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Berkeley
- 类型
- 私人持股
- 领域
- Pharmaceuticals
地点
-
主要
获取路线
US，Berkeley
Carmot Therapeutics, Inc.员工
动态
-
Join us in raising awareness for #WorldObesityDay. Starting a conversation can help us bring understanding to others and make it easier to build momentum towards action. As more than 1 billion people in the world today are living with #obesity, we remain committed to developing life-changing therapeutics. Learn more here: https://lnkd.in/eS38U52 #LetsTalkAboutObesity
-
-
Today we announced the completion of our acquisition by Roche, making Carmot part of Roche’s Pharmaceutical Division. Together we’ll continue to advance three clinical-stage assets in #obesity and #diabetes. Learn more: https://bit.ly/48QGwVT?
-
-
#News: We’re thrilled to announce a definitive merger agreement with Roche. At the closing of the proposed transaction, Carmot and its employees will join the Roche Group as part of Roche’s Pharmaceutical Division to further develop our three clinical-stage assets with the aim of improving the standard of care in treating #obesity and #diabetes, and potentially other diseases. Learn more here: https://bit.ly/46Igrq9
-
-
Thanks to the Obesity Action Coalition for their dedication to advocating for and providing education and resources to those impacted by obesity. We are proud to be a member of the OAC Chairman's Council and look forward to working together to support the obesity community.
Thank you Carmot Therapeutics for your support at the Bronze level of the OAC Chairman's Council!? Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including obesity and diabetes. Members of the OAC Chairman’s Council play an integral role in helping the OAC advocate for and provide education and resources to the millions of individuals affected by the disease of obesity while creating an extensive and unparalleled community of support.? https://lnkd.in/eENQ2Dei
-
-
#News: Excited to share we've commenced a Phase 2 clinical trial of our once-daily, dual GLP-1/GIP receptor agonist, CT-868 for the treatment of Type 1 Diabetes. This brings us one step closer to our mission of developing life-changing therapeutics for people living with metabolic diseases. Learn more: https://bit.ly/3QXDWH5 #T1D
-
-
Today, we are honoring #WorldDiabetesDay by wearing blue to raise awareness of the need for access to diabetes care. Learn more:?https://lnkd.in/dcJMsBe
-
-
Join us in raising awareness for #WorldDiabetesDay. We are committed to developing life-changing therapeutics for people living with diabetes. Check out this video on how our clinical candidates aim to induce weight loss and reduce insulin resistance: https://bit.ly/472DqgD
-